Key statistics
As of last trade ProQR Therapeutics NV (0PQ:STU) traded at 3.65, -8.94% below its 52-week high of 4.01, set on Oct 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.59 |
---|---|
High | 3.65 |
Low | 3.59 |
Bid | 3.64 |
Offer | 3.87 |
Previous close | 3.68 |
Average volume | 27.11 |
---|---|
Shares outstanding | 105.90m |
Free float | 90.55m |
P/E (TTM) | -- |
Market cap | 421.50m USD |
EPS (TTM) | -0.2813 USD |
Data delayed at least 15 minutes, as of Nov 12 2024.
More ▼
Announcements
- ProQR Announces Third Quarter 2024 Operating and Financial Results
- ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement
- ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement
- ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares
- ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society
- ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference
- ProQR Announces Second Quarter 2024 Operating and Financial Results
- ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit
- ProQR Announces First Quarter 2024 Operating and Financial Results
- ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases
More ▼